Catalyst
Slingshot members are tracking this event:
Alder (ALDR) Expects Top-Line Data from Phase III PROMISE 1 Trial Evaluating ALD403 in Frequent Episodic Migraines in H1 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALDR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 27, 2017
Occurred Source:
http://investor.alderbio.com/releasedetail.cfm?ReleaseID=1031418
Related Projects
Related Keywords
Top-line Data, Phase Iii Trial, Promise 1, Ald403, Frequent Episodic Migraines, H1 2017, Eptinezumab
